Revenue segments as reported by the company.

U.S. Pharmaceutical

Prescription Technology Solutions

Medical-Surgical Solutions

International

Corporate

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, distribution, general, and administrative expenses

Claims and litigation charges, net

Restructuring, impairment, and related charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

McKesson

McKesson Corp. engages in the provision of supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. It operates through the following segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products, provides practice management, technology, clinical support, and business solutions to community-based oncology, and other specialty practices, and sells financial, operational, and clinical solutions to pharmacies and provides consulting, outsourcing, technological, and other services. The International segment provides distribution and services to wholesale, institutional, and retail customers in European countries and Canada. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The RxTS segment brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation, including Multi-Client Central Fill as a Service, to serve biopharma and life sciences partners and patients. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

McKesson reports robust fiscal 2023 performance and focuses on sustainability

McKesson's Q4 fiscal 2023 earnings call highlighted strong financial performance, strategic priorities, and a focus on sustainability and employee recognition. The company faces challenges related to operational efficiencies and managing potential impacts from industry dynamics. However, it remains optimistic about opportunities for long-term growth and partnerships in the oncology space.

McKesson reports strong Q1 performance and anticipates sustained growth

McKesson's Q1 fiscal 2024 earnings call showcased strong financial performance, with a focus on prescription volume growth and expansion in the U.S. Oncology Network. The company faces potential fluctuations and timing challenges in its RxTS business but expects to benefit from volume-related factors and continual development. Overall, McKesson is well-positioned for sustainable growth and value creation.

McKesson excels in Q3, eyes oncology growth and sustainability

McKesson's Q3 performance was strong, with raised guidance and progress in strategic priorities.
The company's strengths lie in its focus on oncology, sustainability initiatives, and operational performance.
Challenges include macroeconomic factors, biosimilar management, and margin improvement strategies.
Opportunities in oncology growth, biosimilars, and strategic partnerships pave the way for future success.

McKesson reports robust earnings, poised for sustainable growth in healthcare

McKesson's Q4 2023 earnings call highlighted strong financial performance, strategic advancements, and a commitment to driving sustainable growth in key healthcare segments.
The company's focus on efficiency, sustainability, and employee engagement underpins its competitive strengths and resilience in a dynamic healthcare landscape.
While challenges such as industry fluctuations and regulatory dynamics exist, McKesson's strategic positioning, diverse business lines, and growth opportunities position it for continued success.
By leveraging opportunities in service expansion, biosimilars, and market trends, McKesson aims to enhance patient outcomes, drive revenue growth, and maintain its leadership in the healthcare services sector.

McKesson exceeds Q1 expectations, focuses on supply chain efficiency

McKesson delivered strong first-quarter results, exceeding revenue and earnings expectations.
The company's focus on enhancing supply chain efficiency and expanding relationships with manufacturers is driving growth.
Challenges include non-linear investments and the impact of 340B on pharmaceutical distribution business.
Opportunities lie in benefiting from volume-related factors, supporting product life cycles, and expanding oncology solutions.

McKesson excels in Q2, anticipates growth amid strategic investments

McKesson's Q2 performance reflects strong revenue growth and operational excellence across key segments.
The company's focus on employee well-being, technology solutions, and strategic investments positions it for continued success.
While facing competitive challenges in generics procurement, McKesson maintains stability and customer-centric supply.
Anticipated growth opportunities in fiscal 2024 and beyond underscore McKesson's commitment to innovation and operational efficiency.

McKesson reports robust Q3 earnings, eyes growth through strategic investments

McKesson's Q3 performance reflects strong revenue and earnings growth, supported by strategic initiatives and investments in key segments. While facing challenges like patient visit volumes and margin pressures, the company remains focused on driving sustainable growth and value delivery. Opportunities for growth through technology investments and segment expansions position McKesson for future success.

McKesson reports robust Q4 results, eyes growth in oncology services

McKesson's strong performance in Q4 '24 underscores its leadership in oncology and biopharma services, supported by strategic investments in AI and a new partnership with Optum. While facing challenges in pricing dynamics and 3PL business growth, the company is well-positioned to capitalize on opportunities in inorganic growth, AI utilization, and health equity initiatives.

McKesson reports solid Q1 growth, focuses on pharma innovation

McKesson's Q1 2025 showed solid revenue growth and increased earnings per share, driven by strong performance in pharmaceutical segments.
While facing challenges in the Medical-Surgical segment, the company aims to leverage strengths in distribution and technology investments for future growth.
Opportunities lie in capitalizing on pharmaceutical segment performance and driving innovation through technology investments.
Overall, McKesson's outlook for fiscal 2025 remains positive with projected revenue and profit growth.

McKesson posts record revenue, focuses on oncology for sustained growth

McKesson's strong financial performance and raised guidance reflect its resilience and strategic focus on growth.
While facing regulatory and integration challenges, the company's commitment to innovation and employee well-being positions it well for the future.
Opportunities lie in expanding market presence through acquisitions, influencing policy reforms, and optimizing operational efficiencies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.

McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow

Genpact

Companies co-innovate with leading-edge technologies, advanced analytics, and improved process design to drive strategic business value with McKesson's digital finance operating model optimization  IRVING, Texas and NEW YORK , Aug. 16, 2023 /PRNewswire/ -- McKesson (NYSE: MCK), a diversified healthcare services leader, and Genpact (NYSE: G), a global professional services firm focused on delivering outcomes that transform businesses, today announced that they have extended their relationship to bring continued efficiency and automation capabilities to McKesson's finance operations, utilizing automation and AI solutions. The extension builds on a 13-year association of simplifying and standardizing McKesson's finance processes, leveraging its vision, operational excellence, and enterprise strategy roadmap, combined with Genpact's process expertise.

Genpact Extends Relationship to Transform McKesson's Finance Operations for Enhanced Service and Competitive Growth

Clorox

Uber

The Q2 earnings season is nearly in the books. As of Aug. 4, 84% of the S&P 500 had reported their results.

3 Most Surprising Takeaways from Q2 Earnings Season

Activision Blizzard

Celanese

Capital One

Chevron

D.R. Horton

Globe Life Inc

General Motors

Marsh & McLennan

Occidental Petroleum

Berkshire Hathaway bought shares of five different stocks in the second quarter, including three new positions. The conglomerate was a net seller of stocks, selling shares of seven different companies.

Here Are All 5 Stocks Warren Buffett and His Team Bought in the Second Quarter -- and the 7 Stocks Berkshire Hathaway Sold

Hershey

Dividend hikes reflect a company's commitment to returning value to shareholders, undoubtedly encouraging. And recently, all three of these companies have boosted their payouts.

3 Stocks to Buy on Recent Dividend Hikes

Lennar

Warren Buffett's Berkshire Hathaway Inc. took new stakes in home builders, bulked up on Capital One Financial Corp. and backed away from Activision Blizzard Inc. in the second quarter, according to quarterly disclosures filed on Monday.

Buffett bet on home builders and retreated from videogames during the second quarter

Vitesse Energy Inc

Warren Buffett's Berkshire Hathaway added a trio of homebuilders to its portfolio last quarter. The investor's company exited three stocks and slashed several of its positions, SEC filings show.

Warren Buffett's Berkshire Hathaway bet on 3 homebuilders - and sold and slashed a bunch of stocks last quarter

Atmos Energy

Delta Air Lines

Molina Healthcare

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOH, DAL, ATO and MCK are strong enough to meet financial obligations.

Add These 4 Stocks With Impressive Interest Coverage Ratio

RICHMOND, Va.--(BUSINESS WIRE)--McKesson Medical-Surgical is a silver sponsor of the National Association of Community Health Centers 2023 NHCW Aug. 6-12.

McKesson Medical-Surgical Supports National Health Center Week 2023

McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.

McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong

McKesson (MCK) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $5.83 per share a year ago.

McKesson (MCK) Beats Q1 Earnings and Revenue Estimates

While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

McKesson (MCK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2024 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 2nd at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and.

McKesson Corporation Reports Fiscal 2024 First Quarter Results

McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?

Danaher

Intuitive Surgical

Johnson & Johnson

Eli Lilly

Teladoc

UnitedHealth Group

Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each year, which works out to nearly $13,000 per person.

7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes

Cintas Corp

Landstar System

Voya Financial

Wells Fargo

After years of a low interest rate environment, which is still trending higher, many investors have turned to equities not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.

5 Wall Street Analyst Favorite ‘Strong Buy' Companies Expected to Raise Their Dividends This Week

McKesson Corp. MCK, -1.08% said Monday that it raised its quarterly dividend declared July 21 to $0.62 per share, a 15% increase from $0.54 per share in the prior quarter. “The dividend increase reflects confidence in our strategy and ability to generate sustained strong cash flows,” McKesson CEO Brian Tyler said in a statement.

McKesson boosts quarterly dividend 15%

IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) declared on July 21, 2023 a regular dividend of $0.62 per share of common stock, a 15% increase from $0.54 per share in the prior quarter. The dividend will be payable on October 2, 2023, to stockholders of record on September 1, 2023. “The dividend increase reflects confidence in our strategy and ability to generate sustained strong cash flows,” said Brian Tyler, chief executive officer. “We continue to r.

McKesson Raises Quarterly Dividend by 15% to $0.62 Per Share

GE HealthCare Technologies Inc

Medtronic

Artificial intelligence ( AI ) is aiming to revolutionize the healthcare sector, forging a new era of medical innovation. As we dive into the realm of the top AI healthcare stocks, it's imperative to understand the game-changing potential of this technology.

3 Healthcare Stocks Using AI to Deliver You Healthy Profits

Kenvue

Novo Nordisk

With so much concern about the Federal Reserve and its decision-making implications for forward market trends, investors may do well targeting healthcare stocks. Fundamentally, the underlying sector represents a critical need.

3 Healthcare Stocks to Buy as the Market Gets Defensive

Stocks that stop working don't often get much room in swing trading.

MCK Stock Participation Minimal, Hence The Exit

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its first-quarter fiscal 2024 financial results after market close on Wednesday, August 2, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide prese.

McKesson Corporation Announces First-Quarter Fiscal 2024 Earnings Release Date

MCK is expected to benefit from factors such as an aging population, increasing prescription drug usage, and promising expansion opportunities. Despite concerns about changes in branded insulin pricing, I believe MCK can protect its distribution economics due to its strong position in the value chain and negotiating power with manufacturers. I believe MCK's current 15x NTM will become the new normal as the business continues to scale and become stronger.

McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

News for McKesson Stock (MCK)